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Abstract
Background: Anophthalmia and microphthalmia are etiologically and clinically heterogeneous.
Lenz microphthalmia is a syndromic form that is typically inherited in an X-linked pattern, though
the causative gene mutation is unknown. Townes-Brocks syndrome manifests thumb anomalies,
imperforate anus, and ear anomalies. We present a 13-year-old boy with a syndromic
microphthalmia phenotype and a clinical diagnosis of Lenz microphthalmia syndrome.
Case Presentation: The patient was subjected to clinical and molecular evaluation, including
array CGH analysis. The clinical features included left clinical anophthalmia, right microphthalmia,
anteriorly placed anus with fistula, chordee, ventriculoseptal defect, patent ductus arteriosus,
posteriorly rotated ears, hypotonia, growth retardation with delayed bone age, and mental
retardation. The patient was found to have an approximately 5.6 Mb deletion of 16q11.2q12.1 by
microarray based-comparative genomic hybridization, which includes the SALL1 gene, which causes
Townes-Brocks syndrome.
Conclusions: Deletions of 16q11.2q12.2 have been reported in several individuals, although those
prior reports did not note microphthalmia or anophthalmia. This region includes SALL1, which
causes Townes-Brocks syndrome. In retrospect, this child has a number of features that can be
explained by the SALL1 deletion, although it is not clear if the microphthalmia is a rare feature of
Townes-Brocks syndrome or caused by other mechanisms. These data suggest that rare copy
number changes may be a cause of syndromic microphthalmia allowing a personalized genomic
medicine approach to the care of patients with these aberrations.
Background
Anophthalmia and microphthalmia (A/M) are part of a
spectrum of ocular anomalies that includes coloboma.
These conditions have a combined incidence of about 2/
10,000 births [1-4]. The A/M spectrum may be isolated or
syndromic and is etiologically and clinically heterogene-
ous with substantial phenotypic overlap in many cases.
This makes accurate syndrome identification crucial in
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order to provide families and individuals with appropri-
ate recurrence risk counseling.
One-third of individuals with A/M have associated mal-
formations [4]. Both genetic and environmental causes of
A/M have been noted. Mutations causing a phenotype
that segregates in an autosomal recessive pattern have
been found in PAX6 [5], RAX [6] and CHX10 [7] (MIM
607108, 601881 and 142993, respectively). Mutations in
SOX2  (MIM 184429) [8,9] were recently described in
individuals with A/M that segregates in an autosomal
dominant pattern. Current estimates suggest that up to
15% of individuals with bilateral A/M have a mutation in
SOX2 [9]. Bakrania et al., [10] also found individuals with
deletions of SOX2. Mutations in OTX2  (MIM 600037)
have been reported in up to 5% of individuals with A/M
[9]. Mutations in BCOR (MIM 300485) have been seen in
families with X-linked recessive inheritance of a pheno-
type strikingly similar to Lenz microphthalmia syndrome
[11,12]. Lenz microphthalmia has cardinal manifesta-
tions of microphthalmia, growth retardation and limb
anomalies [13]. Other malformations thought to be typi-
cal of this disorder include microcephaly, cognitive
impairment, protuberant ears, missing upper central inci-
sors, syndactyly, and a cylindrical thorax with sloping
shoulders. However, it is clear that Lenz microphthalmia
is clinically variable and genetically heterogeneous and
prior data show that phenotypes compatible with this
description map both to Xp and Xq, the former caused by
mutations in the BCOR gene (MIM 309800) which causes
a phenotype that overlaps extensively with Lenz microph-
thalmia, and shares the X-linked inheritance pattern in
two families [12,14]. The Xq Lenz locus (MCOPS1 MIM
309800) has not yet been identified [15].
Here we report a patient with syndromic A/M that over-
laps with Lenz microphthalmia syndrome (MIM
309800). Molecular evaluation of this patient showed a
deletion of 16q, which includes the SALL1 gene, which
causes Townes-Brocks syndrome (TBS, MIM 107480).
This finding extends the notion of etiologic heterogeneity
of syndromic microphthalmia and has implications for
the approach to molecular diagnostics for this disorder.
Case Presentation
The patient was born at full term weighing 6 lb 2 oz (~25th
centile) and length was 21 in (~75th centile). He was
apneic at birth and was intubated and transferred to the
NICU. He was weaned from the ventilator at 7 days of age
with no complications. Bilateral clinical anophthalmia
was diagnosed on clinical examination. A cranial CT scan
at one day of age showed mild prominence of the left lat-
eral ventricle. A small cavum septum pellucidum was also
noted. A focal area of parenchymal lucency was noted in
the left parietal parenchyma. This raised the possibility of
an in utero ischemic event. A CT scan of the orbits at 6 days
of age showed some orbital contents in the right eye with
an abnormal lens and soft tissue overlying the globe, and
his clinical diagnosis was modified to left clinical anoph-
thalmia and right microphthalmia. The left globe had a
small oval focus of soft tissue, but this tissue could not
confidently be determined to be optic. The optic nerves
appeared severely hypoplastic. A cranial MRI done at 7
days of age identified absent optic nerves with a small
optic chiasm. Renal ultrasound at 2 days of age showed
the kidneys measured 3.7 cm bilaterally (normal 4.0-6.0
cm). Echocardiogram identified a small ventriculoseptal
defect and patent ductus arteriosus, which both resolved
spontaneously. He was also noted to have an anteriorly
placed anus with a fistula that was corrected surgically at
2 months of age.
Clinical Genetics evaluation was performed at 5 years 9
months by one of the authors. Additional history at the
time of this evaluation showed he failed to meet multiple
developmental milestones. His height was 102 cm (<<5th
centile; 50th  centile for 4 years), weight 29.5 pounds
(<<5th centile; ~50th centile for 2 years 6 months), and
head circumference was 50 cm (10-25th centile). In addi-
tion to the findings described above, he was found to have
apparently small, overfolded, and cupped ears, long trunk
with narrow shoulders, low set thumbs, and partial cuta-
neous syndactyly of toes 4-5. Peripheral blood karyotype
was performed at the referring institution and was
reported as normal, 46,XY. The patient was diagnosed
with Lenz microphthalmia syndrome (OMIM 309800
MCOPS1). Complete sequencing of coding exons and
flanking introns of BCOR (the single known Lenz syn-
drome gene) was normal (data not shown).
He was recently re-evaluated at the age of 13 years. He was
treated with melatonin to help with his sleep cycle. On
examination, his weight was 65 lbs (<<5th centile; ~50th
centile for 9 year old), Height 57 in (~10th centile) and
head circumference 52.5 cm (~10th centile). In addition to
the previously mentioned findings, he had multiple nevi
on his chest, back, and limbs. All were 0.3 cm or less. He
has made developmental progress but is in special educa-
tion. Sequencing of SOX2 was normal (data not shown).
The array platform was of the oligonucleotide CGH type
with average genome spacing of 37 kb and targeted probes
in candidate gene regions with 5-20 kb probe spacing (for
details see http://www.genedx.com/site/genomedx).
Hybridization was performed on DNA isolated from
peripheral blood leukocytes as previously described [16].
This assay identified an approximately 5.6 Mb deletion of
chromosome 16. The deletion likely has a minimum
boundary size of Chr16:45,018,886 - 50,571,154
(Human Genome Build 36) and includes 26 known genesBMC Medical Genetics 2009, 10:137 http://www.biomedcentral.com/1471-2350/10/137
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(Table 1). This deletion was not present in the parents.
The deletion of SALL1 was confirmed by a MLPA assay
using the SALSA MLPA kit P180 (MRC Holland, data not
shown). Assessment of 6 STRP markers on chromosome
16 showed inheritance of alleles consistent with biologic
parentage. The proband is apparently homo/hemizygous
at marker D16S3396  (Chr16:49,749,809 - 49,750,146)
and does not share an allele with the mother suggesting
the deletion occurred on the maternal chromosome. We
conclude that this variant is de novo in the proband.
Conclusions
We report a boy with microdeletion of 16q11.2q12.1
identified by array CGH. Microdeletion of 16q11.2q12.2
has been reported as an emerging microdeletion syn-
drome [17]. That report includes two patients with micro-
deletions of 16q that overlap the deletion seen in the
patient reported here. All three patients share similar cen-
tromeric endpoints (as defined by the last centromeric oli-
gonucleotide detected as a single-copy) and two of the
three patients share similar telomeric endpoints. The dele-
tion in Patient 1 in Ballif et al [17] extended an additional
1.4 Mb towards the telomere when compared to the
present patient. Other patients with deletions of
16q11q12 have been reported with limited molecular
data (Table 2).
The deleted region in the patient reported here includes
26 genes, including three recognized disease-causing
genes (Table 1). This list includes the SALL1 gene, which
when mutated causes Townes-Brocks syndrome [18].
Individuals with whole gene deletions have a milder phe-
notype than those who have dominant negative point
mutations [19]. The classic phenotype for TBS includes
imperforate anus, dysplastic ears with hearing impair-
ment, and thumb malformations, although many affected
patients do not have the typical phenotypic features. Less
frequent manifestations of TBS include renal, heart, foot,
and genitourinary anomalies, and mental retardation.
This patient has a number of phenotypic manifestations
that are not typical of TBS including A/M, cognitive
impairment, borderline small head size, growth retarda-
tion, abnormal body habitus, and relatively normal
thumbs. According to Kohlhase, the clinical diagnosis of
TBS requires two of:
* Imperforate anus
* Dysplastic ears (overfolded superior helices, microtia)
* Typical thumb malformations (preaxial polydactyly,
triphalangeal thumbs, hypoplastic thumbs) without
shortening of the radius http://www.ncbi.nlm.nih.gov/
sites/GeneTests/?db=GeneTests
Table 1: Genes in the deleted region
Gene Name Description Transcription Start
SHCBP1 SHC SH2-domain binding protein 1 45,171,968
VPS35 vacuolar sorting protein 35 45,251,089
ORC6L origin recognition complex subunit 6 45,281,058
MYLK3 myosin light chain kinase 3 45,293,694
GPT2 alanine aminotransferase 2 45,476,602
DNAJA2 DnaJ subfamily A member 2 45,546,774
NETO2 neuropilin- and tolloid-like protein 2 45,672,942
ITFG1 integrin alpha FG-GAP repeat containing 1 45,746,798
PHKB phosphorylase kinase, beta isoform a 46,052,710
ABCC12 ATP-binding cassette protein C12 46,674,384
ABCC11 ATP-binding cassette protein C11 46,758,322
LONP2 peroxisomal LON protease-like 46,835,711
SIAH1 seven in absentia homolog 1 isoform a 46,951,946
N4BP1 Nedd4 binding protein 1 47,130,137
CBLN1 cerebellin 1 precursor 47,869,711
ZNF423 zinc finger protein 423 48,082,021
TMEM188 transmembrane protein 188 48,616,689
HEATR3 HEAT repeat containing 3 48,657,381
PAPD5 PAP associated domain containing 5 48,745,568
ADCY7 adenylate cyclase 7 48,879,323
BRD7 Bromodomain containing 7 48,910,441
NKD1 naked cuticle homolog 1 49,139,741
SNX20 sorting nexin-20 49,257,711
NOD2 nucleotide-binding oligomerization domain 49,288,550
CYLD ubiquitin carboxyl-terminal hydrolase CYLD 49,333,461
SALL1 sal-like 1 49,727,386B
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) Table 2: Summary of patients with proximal 16 deletions. 
Patient Chromosomal 
Region
Methodology Molecular 
deletion 
(minimal)
Hand/Foot 
malformation
Anal 
Malformations
Low Set/
Dysmorphic 
Ears
Growth 
Retardation
Hypotonia MR/DD
Present Case 16q11.2q12.1 oligonucleotide 
aCGH
Chr16: 
45,018,886 -- 
50,571,154
Low-set thumbs, 
partial 4,5 toe 
syndactyly
+++ + +
1A 16q11.1q12.1 550 band 
karyotype
ND Proximally placed 
thumbs, short 
distal phalanges
-+-- +
1B 
(sister of 1A)
16q11.1q12.1 550 band 
karyotype
ND Proximally placed 
thumbs, short 
distal phalanges
-++ - +
2 16q11.2q21 CGH/FISH Chr16:49,728,524
-62,004,665
(YAC 922f01-
PAC 
LLNLP704M0311
26Q4)
Radial hypoplasia, 
preaxial 
polydactyly, 
malpositioned 
toes
++- N A N A
3A 16q11.2q12.2 oligonucleotide 
aCGH
chr16:45,058,042-
52,009,874
Malpositioned 
toes, syndactyly
-+- + +
3B 16q11.2q12.2 oligonucleotide 
aCGH
chr16:45,058,042-
50,485,941
Malpositioned 
toes
Rectal prolapse + - + +
4 16q11.1q13 high resolution 
karyotype
ND Malpositioned 
toes
-++ + +
5,6 16q12.1q12.2 650 band 
karyotype/
somatic cell 
hybrids
chr16:49,028,856
(D16S308)
Malpositioned 
toes, long fingers
-+
deafness
++ +
7 16q12.1q12.2 BAC aCGH/FISH chr16:50,271,170-
52,727,176
(BAC RP11-
242n20-RP11-
324d17)
Radial hypoplasia, 
syndactyly
-N A-+ +
8 16q12.1q12.2 qPCR Chr16:47,900,000
-49,800,000 
(approx.)
Long thumbs + +
deafness
-N A +
9A 16q12.1q13 850 band 
karyotype
ND Malpositioned 
toes, syndactyly, 
small hands and 
feet
-+
deafness
++ +
9B
twin of 9A
16q12.1q13 850 band 
karyotype
ND Malpositioned 
toes, syndactyly, 
small hands and 
feet
+++ + +
ND is not done, NA is not assessed, aCGH is array comparative genomic hybridization, BAC is bacterial artificial chromosome, FISH is fluorescence in situ hybridization, and qPCR is quantitative 
polymerase chain reaction.
References for Case numbers: 1 Hoo et al. [30], 2 Knoblauch et al. [31], 3 Ballif et al. [16], 4 Krauss et al. [32], 5 Schuffenhauer et al [33], 6 Callen et al. [34] (this patient was described in two 
papers), 7 Matthaei et al. [35], 8 Borozdin et al. [18], 9 Elder et al. [36]BMC Medical Genetics 2009, 10:137 http://www.biomedcentral.com/1471-2350/10/137
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The present patient only has one of these manifestations
and therefore does not meet these stringent clinical crite-
ria, though as noted above, the phenotype is acknowl-
edged to be variable. One may speculate that an anterior-
placed anus with a fistula is reminiscent of TBS, however
it does not formally meet the criteria.
In contrast, the classical manifestations of Lenz microph-
thalmia are microphthalmia, growth retardation, and ear
anomalies, all of which this patient manifested [13].
Clearly, this triad is not specific for Lenz microphthalmia
and it is reported that > 90% have cognitive impairment
[20], as seen in the present patient. A variety of skeletal
and limb manifestations have been reported, although
frequency data are not available.
Although some of the clinical features of the present
patient overlap with the patients previously reported with
16q11.2 deletions and patients with TBS, the patient
reported here had a major anomaly, A/M, which is clearly
atypical for either of these molecular lesions. Microph-
thalmia has been reported in a pair of twins with TBS and
a point mutation in SALL1 [21] and a patient from the
pre-molecular era with a clinical phenotype consistent
with TBS [22]. There are several possible hypotheses to
explain this observation. First, it is possible that A/M is a
very uncommon manifestation of TBS. Insofar as the
twins reported by Botzenart et al are concerned, it is
remarkable that although both twins had unilateral
microphthalmia, neither their TBS-affected siblings nor
their TBS-affected father had microphthalmia. It is
reported that microphthalmia is two to five times more
common in twins than in singletons [23,24], which limits
the utility of this case in assigning causality of the micro-
phthalmia in this pair of twins to the SALL1 mutation.
Second it is possible that the deleted region in the patient
reported here includes a gene, that when deleted, leads to
A/M but with reduced penetrance. The prior report of a
single patient with the co-occurrence of TBS and microph-
thalmia is intriguing [22] in this regard. As this patient has
not be characterized molecularly and is now deceased
(A.R. Cooper, personal communication), we cannot
determine if that child had microphthalmia and TBS
because of a 16q deletion or that s/he had a point muta-
tion in SALL1 and microphthalmia is a rare manifestation
of TBS. The third possibility is that in the present patient
and the patient reported by Fraser and Cooper, [22] the
16q11.2q12.2 deletion is in trans with another variant,
likely to be uncommon, that leads to a null for a putative
A/M gene in this interval. It will be important to analyze
additional cases with deletions of this region to distin-
guish these two hypotheses.
The deletion region also includes the genes NOD2 associ-
ated with Blau syndrome (OMIM 266600) [25] and CYLD
associated with Brooke-Spiegler syndrome (MIM 605041)
[26]. Missense mutations in NOD2 cause Blau syndrome
and an increased susceptibility to Crohn's disease (MIM
266600) [27]. Blau syndrome is inherited in an auto-
somal dominant pattern and characterized by early-onset
granulomatous arthritis, rashes, and camptodactyly. Ocu-
lar manifestations include uveitis, glaucoma, retinal
detachment, and cataract [28,29]. No published reports of
A/M and Blau syndrome were identified (negative results
from PubMed using the two search strings: "anophth*
AND Blau" and "microphth* AND Blau").
Heterozygous loss of function mutations in CYLD cause
Brooke-Spiegler syndrome, which is characterized by a
number of rare skin appendage tumors such as cylin-
droma, trichoepithelioma, and spiradenoma [30]. Early
detection and aggressive treatment can prevent the signif-
icant deformity that can be caused by these tumors. These
data suggest that the molecular delineation of this dele-
tion in this patient present an opportunity to provide pre-
symptomatic care that will significantly ameliorate the
morbidity of this syndrome.
The patient reported here shares some clinical findings
with the two previously reported patients [17] with dele-
tion 16q11.2;12.2 namely; ear anomalies, toe abnormali-
ties, hypotonia, and significant developmental delay.
Interestingly, Patient 2 from Ballif et al., [17] was reported
to have scattered pigmentary nevi, which was also found
in the patient reported here.
We conclude from these data that the pleiotropic syn-
drome in this patient is caused by the deletion, which was
detected by array CGH. The phenotype in this patient has
some similarities to Townes-Brocks syndrome and to Lenz
microphthalmia. The other suggestion from this report is
that array CGH analysis should be considered in all
patients with syndromic A/M. This is in addition to previ-
ous recommendations that such patients undergo chro-
mosome analysis and SOX2 mutation analysis [9,10].
List of abbreviations
A/M: anophthalmia or microphthalmia; CGH: compara-
tive genomic hybridization; aCGH: array CGH; TBS:
Townes Brocks syndrome;
Consent
The parent of this minor patient has given written consent
for the report to be published. The patient was also con-
sented to a clinical research protocol reviewed and
approved by the NHGRI IRB.
Competing interests
The authors declare that they have no competing interests.BMC Medical Genetics 2009, 10:137 http://www.biomedcentral.com/1471-2350/10/137
Page 6 of 7
(page number not for citation purposes)
Authors' contributions
TMB wrote the first draft of the manuscript. ASS and DN
examined the patient and edited the manuscript. JJJ
designed, interpreted, and performed some of the molec-
ular evaluations, reviewed the literature, and wrote signif-
icant portions of the manuscript. LGB designed and
interpreted some of the molecular evaluations, examined
the patient, and wrote significant portions of the manu-
script. All authors have reviewed and approved the sub-
mission of the manuscript.
Acknowledgements
Funding for ASS and TMB was provided by the Albert B. Millett Memorial 
Fund, A Mellon Mid-Atlantic Charitable Trust, Rae S. Uber Trust, and the 
Gustavus and Louise Pfeiffer Research Foundation. Funding for JJJ, DN, and 
LGB was provided by the Intramural Research Program of the National 
Human Genome Research Institute of the National Institutes of Health. 
The authors are grateful to the family for their support of this description 
of their son and their support of the International Anophthalmia Children's 
Network. Aradhya Swaroop, Ph.D., of GeneDx Corp. provided informa-
tion on the array platform.
References
1. Clementi M, Tenconi R, Bianchi F, Botto L, Calabro A, Calzolari E,
Cianciulli D, Mammi I, Mastroiacovo P, Meli P, Spagnolo A, Turolla L,
Volpato S: Congenital eye malformations: a descriptive epide-
miologic study in about one million newborns in Italy.  Birth
Defects Orig Artic Ser 1996, 30:413-424.
2. Kallen B, Robert E, Harris J: The descriptive epidemiology of
anophthalmia and microphthalmia.  Int J Epidemiol 1996,
25:1009-1016.
3. Dolk H, Busby A, Armstrong BG, Walls PH: Geographical varia-
tion in anophthalmia and microphthalmia in England, 1988-
94.  BMJ 1998, 317:905-909. discussion 910.
4. Morrison D, FitzPatrick D, Hanson I, Williamson K, van Heyningen V,
Fleck B, Jones I, Chalmers J, Campbell H: National study of micro-
phthalmia, anophthalmia, and coloboma (MAC) in Scotland:
investigation of genetic aetiology.  Journal of Medical Genetics
2002, 39:16-22.
5. Glaser T, Jepeal L, Edwards JG, Young SR, Favor J, Maas RL: PAX6
gene dosage effect in a family with congenital cataracts, ani-
ridia, anophthalmia and central nervous system defects.
Nature Genetics 1994, 7:463-471.
6. Voronina VA, Kozhemyakina EA, O'Kernick CM, Kahn ND, Wenger
SL, Linberg JV, Schneider AS, Mathers PH: Mutations in the human
RAX homeobox gene in a patient with anophthalmia and
sclerocornea.  Human Molecular Genetics 2004, 13:315-322.
7. Ferda Percin E, Ploder LA, Yu JJ, Arici K, Horsford DJ, Rutherford A,
Bapat B, Cox DW, Duncan AM, Kalnins VI, Kocak-Altintas A, Sowden
JC, Traboulsi E, Sarfarazi M, McInnes RR: Human microphthalmia
associated with mutations in the retinal homeobox gene
CHX10.  Nature Genetics 2000, 25:397-401.
8. Male A, Davies A, Bergbaum A, Keeling J, FitzPatrick D, Mackie Ogil-
vie C, Berg J: Delineation of an estimated 6.7 MB candidate
interval for an anophthalmia gene at 3q26.33-q28 and
description of the syndrome associated with visible chromo-
some deletions of this region.  European Journal of Human Genetics
2002, 10:807-812.
9. Ragge NK, Lorenz B, Schneider A, Bushby K, de Sanctis L, de Sanctis
U, Salt A, Collin JR, Vivian AJ, Free SL, Thompson P, Williamson KA,
Sisodiya SM, van Heyningen V, Fitzpatrick DR: SOX2 anophthalmia
syndrome.  Am J Med Genet A 2005, 135:1-7. discussion 8.
10. Bakrania P, Robinson DO, Bunyan DJ, Salt A, Martin A, Crolla JA,
Wyatt A, Fielder A, Ainsworth J, Moore A, Read S, Uddin J, Laws D,
Pascuel-Salcedo D, Ayuso C, Allen L, Collin JR, Ragge NK: SOX2
anophthalmia syndrome: 12 new cases demonstrating
broader phenotype and high frequency of large gene dele-
tions.  Br J Ophthalmol 2007, 91:1471-1476.
11. Hilton E, Johnston J, Whalen S, Okamoto N, Hatsukawa Y, Nishio J,
Kohara H, Hirano Y, Mizuno S, Torii C, et al.: BCOR analysis in
patients with OFCD and Lenz microphthalmia syndromes,
mental retardation with ocular anomalies, and cardiac later-
ality defects.  European Journal of Human Genetics 2009.
12. Ng D, Thakker N, Corcoran CM, Donnai D, Perveen R, Schneider A,
Hadley DW, Tifft C, Zhang L, Wilkie AO, Smagt JJ van der, Gorlin RJ,
Burgess SM, Bardwell VJ, Black GC, Biesecker LG: Oculofaciocardi-
odental and Lenz microphthalmia syndromes result from
distinct classes of mutations in BCOR.  Nat Genet 2004,
36:411-416.
13. Jones KL: Smith's Recognizable Patterns of Human Malformation 6th edi-
tion. Philadelphia: Elsevier Saunders; 2006. 
14. Hilton E, Johnston J, Whalen S, Okamoto N, Hatsukawa Y, Nishio J,
Kohara H, Hirano Y, Mizuno S, Torii C, et al.: BCOR analysis in
patients with OFCD and Lenz microphthalmia syndromes,
mental retardation with ocular anomalies, and cardiac later-
ality defects.  European Journal of Human Genetics 2009,
17:1325-1335.
15. Graham CA, Redmond RM, Nevin NC: X-linked clinical anoph-
thalmos. Localization of the gene to Xq27-Xq28.  Ophthalmic
Paediatr Genet 1991, 12:43-48.
16. Piton A, Michaud JL, Peng H, Aradhya S, Gauthier J, Mottron L, Cham-
pagne N, Lafreniere RG, Hamdan FF, Joober R, Fombonne E, Mari-
neau C, Cossette P, Dube MP, Haghighi P, Drapeau P, Barker PA,
Carbonetto S, Rouleau GA: Mutations in the calcium-related
gene IL1RAPL1 are associated with autism.  Human Molecular
Genetics 2008, 17:3965-3974.
17. Ballif BC, Theisen A, McDonald-McGinn DM, Zackai EH, Hersh JH,
Bejjani BA, Shaffer LG: Identification of a previously unrecog-
nized microdeletion syndrome of 16q11.2q12.2.  Clinical Genet-
ics 2008, 74:469-475.
18. Kohlhase J, Wischermann A, Reichenbach H, Froster U, Engel W:
Mutations in the SALL1 putative transcription factor gene
cause Townes-Brocks syndrome.  Nature Genetics 1998,
18:81-83.
19. Borozdin W, Steinmann K, Albrecht B, Bottani A, Devriendt K,
Leipoldt M, Kohlhase J: Detection of heterozygous SALL1 dele-
tions by quantitative real time PCR proves the contribution
of a SALL1 dosage effect in the pathogenesis of Townes-
Brocks syndrome.  Human Mutation 2006, 27:211-212.
20. Gorlin RJ, Cohen MM Jr, Hennekam RCM: Syndromes of the head and
neck 4th edition. Oxford: Oxford University Press; 2001. 
21. Botzenhart EM, Bartalini G, Blair E, Brady AF, Elmslie F, Chong KL,
Christy K, Torres-Martinez W, Danesino C, Deardorff MA, Fryns JP,
Marlin S, Garcia-Minaur S, Hellenbroich Y, Hay BN, Penttinen M,
Shashi V, Terhal P, Van Maldergem L, Whiteford ML, Zackai E, Kohl-
hase J: Townes-Brocks syndrome: twenty novel SALL1 muta-
tions in sporadic and familial cases and refinement of the
SALL1 hot spot region.  Human Mutation 2007, 28:204-205.
22. Fraser F, Cooper A: Micropthalmia as part of the townes syn-
drome.  Proceedings of the Greenwood Genetics Center 1985, 4:129.
23. Li SJ, Ford N, Meister K, Bodurtha J: Increased risk of birth
defects among children from multiple births.  Birth Defects Res
A Clin Mol Teratol 2003, 67:879-885.
24. Shaw GM, Carmichael SL, Yang W, Harris JA, Finnell RH, Lammer EJ:
Epidemiologic characteristics of anophthalmia and bilateral
microphthalmia among 2.5 million births in California, 1989-
1997.  Am J Med Genet A 2005, 137:36-40.
25. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu
S, Hafner R, Chamaillard M, Zouali H, Thomas G, Hugot JP: CARD15
mutations in Blau syndrome.  Nature Genetics 2001, 29:19-20.
26. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R,
Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E,
Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C,
Beemer FA, Ouweland A van Den, Halley D, Delpech B, Cleveland
MG, Leigh I, Leisti J, Rasmussen S: Identification of the familial
cylindromatosis tumour-suppressor gene.  Nature Genetics
2000, 25:160-165.
27. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J,
Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot
A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J,
Colombel JF, Sahbatou M, Thomas G: Association of NOD2 leu-
cine-rich repeat variants with susceptibility to Crohn's dis-
ease.  Nature 2001, 411:599-603.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Genetics 2009, 10:137 http://www.biomedcentral.com/1471-2350/10/137
Page 7 of 7
(page number not for citation purposes)
28. Blau EB: Familial granulomatous arthritis, iritis, and rash.  J
Pediatr 1985, 107:689-693.
29. Pastores GM, Michels VV, Stickler GB, Su WP, Nelson AM, Boven-
myer DA: Autosomal dominant granulomatous arthritis,
uveitis, skin rash, and synovial cysts.  J Pediatr 1990,
117:403-408.
30. Scheinfeld N, Hu G, Gill M, Austin C, Celebi JT: Identification of a
recurrent mutation in the CYLD gene in Brooke-Spiegler
syndrome.  Clin Exp Dermatol 2003, 28:539-541.
31. Hoo JJ, Lowry RB, Lin CC, Haslam RH: Recurrent de novo inter-
stitial deletion of 16q in two mentally retarded sisters.  Clinical
Genetics 1985, 27:420-425.
32. Knoblauch H, Thiel G, Tinschert S, Korner H, Tennstedt C, Chaoui
R, Kohlhase J, Dixkens C, Blanck C: Clinical and molecular
cytogenetic studies of a large de novo interstitial deletion
16q11.2-16q21 including the putative transcription factor
gene SALL1.  Journal of Medical Genetics 2000, 37:389-392.
33. Krauss CM, Caldwell D, Atkins L: Interstitial deletion and ring
chromosome derived from 16q.  Journal of Medical Genetics 1987,
24:308-312.
34. Schuffenhauer S, Callen DF, Seidel H, Shen Y, Lederer G, Murken J:
De novo interstitial deletion 16(q12.1q13) of paternal origin
in a 10-year-old boy.  Clinical Genetics 1992, 42:246-250.
35. Callen DF, Eyre H, Lane S, Shen Y, Hansmann I, Spinner N, Zackai E,
McDonald-McGinn D, Schuffenhauer S, Wauters J, et al.: High reso-
lution mapping of interstitial long arm deletions of chromo-
some 16: relationship to phenotype.  Journal of Medical Genetics
1993, 30:828-832.
36. Matthaei A, Werner W, Gerlach EM, Koerner U, Tinschert S, Nitz I,
Herr A, Rump A, Bartsch O, Hinkel KG, Schrock E, Oexle K: Small
reciprocal insertion detected by spectral karyotyping (SKY)
and delimited by array-CGH analysis.  Eur J Med Genet 2005,
48:328-338.
37. Elder FF, Ferguson JW, Lockhart LH: Identical twins with deletion
16q syndrome: evidence that 16q12.2-q13 is the critical band
region.  Human Genetics 1984, 67:233-236.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/10/137/pre
pub